Epioxa from Glaukos is the first epithelium-on corneal cross-linking treatment that has been FDA approved in the United States.While epi-on cross-linking has been common abroad for a number of years, Rajesh K. Rajpal, MD, said the procedure now has the potential to make a big difference for U.S. patients.“It’s a streamlined treatment because the UV light source is a higher-energy light combined with oxygen enrichment that enables the more efficient type II cross-linking. This helps overall for patients in terms of the amount of time their eyes are open and the amount of time they’re getting
